BrainsWay (BWAY) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Achieved record Q2 2025 revenue of $12.6 million, a 26% year-over-year increase, with net profit rising to $2.0 million, up 233% from Q2 2024.
Shipped 88 Deep TMS systems, a 35% increase year-over-year, expanding the installed base to 1,522 systems.
Multi-year lease agreements now account for 70% of customer engagement, driving recurring revenue and high retention, with $62 million in remaining performance obligations, up 25% year-over-year.
Strategic minority investments initiated, including a $5 million investment in Stellar MSL and partnerships with Valor Equity Partners.
Backlog of signed agreements provides strong future revenue visibility.
Financial highlights
Gross profit reached $9.5 million, up from $7.5 million year-over-year, with a stable 75% gross margin.
Operating profit was $600,000, consistent with the prior year.
Adjusted EBITDA increased to $1.5 million from $1.3 million year-over-year.
Net profit rose to $2 million from $0.6 million in Q2 2024; basic EPS $0.05.
Ended the quarter with $78.3 million in cash and equivalents, including $10.1 million in short-term deposits.
Outlook and guidance
Full-year 2025 revenue guidance raised to $50–$52 million, representing 22%–27% growth over 2024.
Expected operating profit margin of 4%–5% and adjusted EBITDA margin of 12%–13% for 2025.
Plans to sign at least five new minority investment contracts in 2025, targeting 15 by end of 2026.
Business momentum and recurring revenue streams from multi-year agreements support improved visibility.
Latest events from BrainsWay
- 27% revenue growth and 161% net income surge in 2025, with strong outlook for 2026.BWAY
Q4 202518 Mar 2026 - Q2 revenue up 28%, profitability sustained, and FDA expands Deep TMS use to age 86.BWAY
Q2 20242 Feb 2026 - Q3 revenue up 26%, profitability sustained, and guidance raised with new equity financing.BWAY
Q3 202415 Jan 2026 - Record revenue, profitability, and global expansion set stage for strong 2025 growth.BWAY
Q4 202426 Dec 2025 - Shelf registration enables up to $100M in flexible securities offerings to support growth and R&D.BWAY
Registration Filing16 Dec 2025 - Registration enables a major shareholder to resell up to 3.6 million ADSs, with potential dilution.BWAY
Registration Filing16 Dec 2025 - Strong growth, recurring revenue, and clinical innovation position the company for global expansion.BWAY
Investor Presentation2 Dec 2025 - Accelerated protocols, recurring revenue, and Deep TMS expansion drive breakout growth in 2026.BWAY
Analyst & Investor Day 20251 Dec 2025 - Q1 revenue up 27% with record profit growth, strong margins, and expanding clinical pipeline.BWAY
Q1 202521 Nov 2025